Chimerix Inc (CMRX)
0.9944
+0.02
(+2.54%)
USD |
NASDAQ |
May 17, 16:00
0.9944
0.00 (0.00%)
After-Hours: 20:00
Chimerix Research and Development Expense (Annual): 68.79M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 68.79M |
| December 31, 2022 | 71.63M |
| December 31, 2021 | 73.82M |
| December 31, 2020 | 36.23M |
| December 31, 2019 | 42.29M |
| December 31, 2018 | 55.24M |
| December 31, 2017 | 49.45M |
| Date | Value |
|---|---|
| December 31, 2016 | 58.65M |
| December 31, 2015 | 97.72M |
| December 31, 2014 | 45.38M |
| December 31, 2013 | 24.66M |
| December 31, 2012 | 30.11M |
| December 31, 2011 | 30.11M |
| December 31, 2010 | 19.41M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
36.23M
Minimum
2020
73.82M
Maximum
2021
58.55M
Average
68.79M
Median
2023
Research and Development Expense (Annual) Benchmarks
| UFP Technologies Inc | -- |
| Dentsply Sirona Inc | 184.00M |
| Arbutus Biopharma Corp | 73.70M |
| Pacira BioSciences Inc | 76.26M |
| Karyopharm Therapeutics Inc | 138.75M |